Clinical Trial Update: A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers [Phase 2]

View source ↗

Summary

Phase II safety and immunogenicity trial of live recombinant Canarypox ALVAC-HIV vCP205 with or without HIV-1 SF-2 gp120 in HIV-uninfected adults; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• ALVAC-HIV vCP205 (live recombinant Canarypox) (ALVAC-HIV vCP205)
• HIV-1 SF-2 gp120 (gp120)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED